Highlights BenevolentAI

Equities

BAI

LU2355630455

Market Closed - Euronext Amsterdam Other stock markets 07:21:29 28/06/2024 pm IST			5-day change	1st Jan Change
0.488 ^EUR	-2.40%		-6.15%	-54.81%

25/06	BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed into Portfolio	CI
15/05	BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed into Portfolio	25/06	CI
BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected	15/05	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	03/04	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	02/04	MT
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	02/04	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	25/03	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	26/23/26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	20/23/20	MT
BenevolentAI Signs Strategic Collaboration with Merck	20/23/20	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	31/23/31	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	05/23/05	CI
BenevolentAI Announces New Preclinical Data on Ai-Generated Target Identified in Their Ongoing Collaboration with Astrazeneca	31/23/31	CI
Benevolentai S.A. Launches New Suite of Products	25/23/25	CI
BATM reports Edgility progress, Rambler starts sale	18/23/18	AN
BenevolentAI Announces Top-Line Results from Its Phase IIa, Randomised, Double-Blind, Placebo-Controlled Study of BEN-2293	05/23/05	CI
BenevolentAI société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16	CI
BenevolentAI société anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16	CI
BenevolentAI Submits CTA for BEN-8744, as a First-In-Class Treatment for Ulcerative Colitis	21/22/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BenevolentAI

Equities

BAI

LU2355630455

Highlights

Filters